The relationship between comedo-DCIS and basal-like breast cancer illustrates this point, and suggests that p63/Her2/neu expressions may be used as markers for identifying breast cancers that may progress to a novel clinical subgroup of basal-like breast cancer. Here, ERBB2 is linked to breast cancer.